Navigation Links
GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

patients (8) and a need remains for new treatment options.

"These results clearly demonstrate the potential pazopanib offers as a future therapeutic option not only in renal cell cancer, but across many different tumor types," said Debasish Roychowdhury, MD, Vice President, Global Clinical Development, Oncology Medicine Development Centre, GSK. "The broad clinical development program for pazopanib, in various cancers as monotherapy and in combination therapy, including combinations with Tykerb, underscores our continued commitment to delivering effective new treatments for patients with cancer."

Ovarian cancer study (Abstract 5561) (9)

This ongoing Phase II open-label, monotherapy study is evaluating pazopanib in patients with cancer of the ovary, fallopian tube or peritoneum, who have failed standard platinum-based therapy. Treatment is continued until disease progression, withdrawal due to AEs, or withdrawal of consent. Biological activity (measured as a decrease in CA-125, a biologic marker of clinical activity) was seen in nine (41%) of 22 evaluable patients with relapsed disease. The most common AEs were diarrhea, nausea, abdominal pain, fatigue, and vomiting. Please see safety considerations below.

Globally, ovarian cancer (204,000 cases and 125,000 deaths) is the sixth most common cancer and the seventh most common cause of death from cancer in women. (5) The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis. Typically, these patients are managed with surgery followed by combination chemotherapy. Although the majority of patients will respond initially to firstline therapy, recurrent disease remains a considerable problem. (10)

Soft tissue sarcoma study (Abstract 10031) (11)

STS is a disease in which malignant cancer cells begin growing in soft tissues, such as muscles, tendons, connective tissues, fat, blood vessels, nerves, and tissues around joints. This ongoing Ph
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
(Date:7/22/2008)...Pilot Study Suggests That Ekkyo,s New Approach of ...ally Improve Scar Healing Physiology, MARSEILLES,...nown as,Heatwave Technology) a photomedicine compa...ems for skin scar prevention and reduction, announ...in Lasers in Surgery and Medicine*,reporting the r...
Breaking Medicine Technology:Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 1Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 4JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 1JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 2JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 3JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 4ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 1ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 2ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 3Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 1Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 2Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 3
...Maintained Stability,Significantly Longer than Pla...Comparable with Placebo , MARIETTA, Ga. and COLLEG..., Inc., Wyeth Pharmaceuticals, a division of Wyeth...tudy results on,bifeprunox, an investigational tre...enia, today at the 2007 annual meeting of,the Amer...
...ire-FirstCall/ -- Forest,Laboratories, Inc. and Cy...inary top-line results from a 1,196 patient random...d pivotal Phase III,study demonstrate statisticall...s a treatment of fibromyalgia syndrome. At this ti...tial top-line,results and further analyses will be...
Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:7/25/2008)...weight or obese is not only a personal issue that ...ssue that impacts other people in society. A new s...eals that the extra Medicare cost associated with ...t financial burden on tax payers, costing up to hu...rrent Medicare population. , The article,s find...
(Date:7/25/2008)...ers tips and encourages them to, ,Speak Up,(TM) f... 25 /PRNewswire-USNewswire/ -- The Pennsylvania,Pa...tient Safety Day" which,is a national effort to en... fully in their healthcare by asking questions and...or illness., "We understand the important role th...
(Date:7/25/2008)...ber of jobs created in the medical field slowed in...nt kind of slowdown: they laid off fewer people in... Seattle, WA (PRWEB) July 25, 2008 -- Thoug...slowed in June overall, pharmaceutical companies r...music to the ears of sales representatives: fewer ...
(Date:7/25/2008)... of Defense and Federal Agencies in, the executio...oenix is a, four-day, multi-agency collaborative... and local agencies with large and complex inciden...ital, ad-hoc, secure mobile communications infra...ORFOLK, Va., July 25 /PRNewswire/ -- Dataline LLC ...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3
...enge releases a dose of nicotine and is one of the...uit smoking.// The federal government has announc...nada. The lozenges are to join nicotine patches, g...er the counter. This decision was taken because th...
...re Commission today came down heavily on senior ma...were responsible for the spread of a lethal bug// ...gets above infection control. A couple of outbrea...pital resulted in 33 deaths far more than the 12 o...
...e-up of community health care could cause a change...e been made to merge the roles of community health...t nurses into one community health job. This could...ss Scotland. These were the plans that were outli...
...shington residents have taken ill after eating raw...t of Health has reported. The Health department ha...oid eating raw shellfish. Oysters that are prope...ut raw oysters may be prone to bacteria that is fo...
Other Medicine News:Health News:"Serious Failings" Led To Spread Of Lethal Hospital Bug 2
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Designed for applications that demand the utmost in biological purity, individually packed Finntip BioCon tips are endotoxin-free, DNA-free, DNase-free and RNase-free. Finntip BioCon tips are guaran
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting.
Medicine Products: